On March 13, 2020, Maxvax was awarded the “Certificate of Innovation Platform Technology” to develop adjuvants for use in COVID-19  vaccines. The award was given by the Chengdu Hi-tech Zone under its policy of supporting “enterprises to develop major innovation platform projects” for the prevention and control of the COVID-19 pandemic.